Australian biopharm Covirix Medical, which is developing a broad-spectrum antiviral, has signed a letter of intent with Aptar Pharma for a feasibility study evaluating delivery of the antiviral via Aptar’s Orbital dry powder inhaler. The study will include formulation development services performed by Aptar subsidiary Nanopharm, the announcement notes. Aptar acquired worldwide rights to the high-payload Orbital device from Pharmaxis in 2022.
According to Covirix’s web site, the antiviral compound is a glucosidase inhibitor. Covirix plans to develop the antiviral as a DPI for the prevention and treatment of viral respiratory infections such as flu, RSV, and COVID-19.
Aptar Pharma Director of Business Development, Pulmonary Category, Jonathan Mulpas commented, “Covirix’s portfolio of antivirals addresses several global challenges, and Aptar Pharma is proud to actively support and accelerate the development of a product that has the potential to help patients worldwide. Our specialized services were created precisely for this purpose, to guide customers through complex regulatory pathways and advance their programs efficiently, backed by more than three decades of deep experience in respiratory drug delivery.”
Covirix CEO Kumud Dhital said, “This collaboration provides access to critical delivery technology and commercial relationships. It accelerates our path to market for a much-needed antiviral solution, creating a win-win for both companies and global public health.”
Read the Aptar Pharma press release
